Aplastic anemia is curable, but only through one route: a stem cell transplant. For patients who receive a transplant from a matched sibling donor, long-term survival reaches 92% in children and 80% or higher in adults under 40. The other main treatment, immunosuppressive therapy, can put the disease into remission and restore blood counts to functional levels, but it is not considered a true cure because relapse and late complications remain ongoing risks.
Which path you’re offered depends on your age, how severe the disease is, and whether a suitable donor is available. Understanding what each treatment can and can’t do is essential for making sense of your prognosis.
What Happens Inside the Bone Marrow
In acquired aplastic anemia, the immune system turns on the body’s own blood-producing stem cells. Rogue immune cells become activated and release a flood of inflammatory signals that drive stem cells into self-destruction. Over time, the marrow empties out. Instead of a factory churning out red cells, white cells, and platelets, you’re left with fatty, depleted tissue that can’t keep up with the body’s demand for new blood.
Because the root problem is immune-driven, treatment targets either the faulty immune response (suppressing it with drugs) or replaces the damaged marrow entirely (with a transplant from a healthy donor). The disease is classified as severe when the marrow is less than 25% of its normal cellularity and at least two blood cell types have dropped to critically low levels.
Stem Cell Transplant: The Only True Cure
A stem cell transplant replaces your damaged marrow with healthy donor cells that rebuild blood production from the ground up. When it works, the disease is gone permanently. A large European study of more than 3,600 patients with severe aplastic anemia found an overall five-year survival rate of 80%, with outcomes improving in recent years as techniques have advanced.
Results vary significantly by donor type and patient age. Children under 18 who receive cells from a matched sibling donor have a three-year survival of 93%. For adults aged 18 to 40 with the same donor type, that number is 87%. Matched unrelated donors produce slightly lower but still strong results: 89% for children and 81% for younger adults. Outcomes decline with age and with less well-matched donors. Adults over 60 receiving a partially matched donor, for example, face substantially lower survival rates.
Current guidelines recommend a matched sibling transplant as first-line treatment for children and younger adults with severe disease when a donor is available. For adults without a sibling match, an unrelated donor transplant is typically considered after immunosuppressive therapy has failed to produce a response, though younger adults with severe infections and a readily available matched unrelated donor may be offered transplant upfront.
Immunosuppressive Therapy: Remission Without Cure
Most adults, especially those over 40 or without a matched donor, are treated with immunosuppressive therapy as the first option. The standard regimen combines drugs that suppress the overactive immune cells with a medication that stimulates platelet production. At six months, roughly 68% of patients achieve a complete or partial response, meaning their blood counts recover enough to reduce or eliminate the need for transfusions.
Recovery isn’t instant. Blood counts typically don’t begin improving for two to three months after treatment starts, and the waiting period requires careful monitoring with transfusion support. Neutrophil counts (the infection-fighting white cells) sometimes tick up within a few weeks, which is an early encouraging sign. About 90% of responses appear within the first three months, with a smaller number of patients responding between three and six months.
Even after a successful response, you’ll stay on immune-suppressing medication for a prolonged period. Doctors gradually taper the dose over months or years, adjusting based on how your blood counts hold. Coming off the medication too quickly raises the risk of relapse.
The Relapse Problem
This is the key difference between a transplant and drug therapy. Immunosuppressive treatment controls the disease but doesn’t eliminate the underlying vulnerability. About 40% of patients who respond to therapy eventually relapse, and around 15% develop a secondary blood cancer, most commonly a pre-leukemic condition called myelodysplastic syndrome. Long-term data tracking patients for up to 25 years show that the risk of these complications never fully plateaus. The last cases of clonal evolution in one study occurred 20 years after treatment.
Transplant recipients face a very different risk profile. Clonal evolution to blood cancers after transplant is rare, occurring in only about 1.3% of patients in long-term follow-up. The marrow is fully replaced, so the original disease process is effectively erased.
Why Age Matters So Much
Age shapes nearly every treatment decision in aplastic anemia. Younger patients tolerate transplants better and have higher cure rates. A study comparing outcomes in nearly 600 children found that those who received a matched family donor transplant had an 87% failure-free survival at 10 years, compared to 56% for children treated with immunosuppressive therapy alone. Overall survival was similar between the two groups (92% vs. 88%), because children who relapsed on drug therapy could often be rescued with a later transplant. But the transplant-first group had fewer long-term complications and a cleaner path forward.
For older adults, the calculus shifts. Transplant-related complications increase with age, and the conditioning regimens needed to prepare the body for new marrow cells are harder to tolerate. Patients over 40 are generally started on immunosuppressive therapy, with transplant held in reserve if the drugs don’t work. Patients over 60, particularly those with other health conditions, require individualized planning.
Non-Severe Aplastic Anemia
Not everyone with aplastic anemia needs aggressive treatment right away. Non-severe cases, where blood counts are low but haven’t dropped to critical thresholds, may be monitored with supportive care like transfusions while doctors watch for progression. If counts drop further or symptoms worsen, treatment follows the same decision tree as severe disease. The line between “watch and wait” and “treat now” is drawn based on specific blood count thresholds: neutrophils below 500 per microliter, platelets below 20,000, and very low numbers of young red blood cells (reticulocytes) signal severe disease requiring prompt intervention.
Life After Treatment
Survivors of aplastic anemia face long-term monitoring regardless of which treatment they received. For transplant recipients, chronic graft-versus-host disease is the most significant ongoing concern. This happens when donor immune cells recognize the recipient’s tissues as foreign and mount a sustained attack, most commonly affecting the skin, lungs, and liver. Patients with chronic graft-versus-host disease often need prolonged courses of steroids, which carry their own side effects including bone thinning.
Secondary cancers can appear decades later. In one study tracking pediatric transplant survivors for nearly 40 years, skin cancers were the most common, followed by breast cancers appearing 20 to 30 years post-transplant. Thyroid abnormalities occurred more often in patients whose conditioning regimen included total body irradiation. On the positive side, patients who received standard conditioning without radiation generally showed normal growth and development, and many went on to have healthy pregnancies.
For those treated with immunosuppressive therapy, the main long-term concerns are relapse and the slow-developing risk of blood cancers. Regular blood count monitoring continues for years, and any unexplained drop in counts warrants prompt evaluation. The 25-year cumulative risk of developing a myeloid malignancy after immunosuppressive therapy is about 16%, reinforcing the need for lifelong follow-up even when initial treatment is successful.